secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2026-09-14T23:12:37+00:00
Accession:  0001193125-26-390951
Event type: other_material
Sentiment:  neutral
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences prices $400M offering of common stock and pre-funded warrants
------------------------------------------------------------------------------

- 9,079,000 shares priced at $22.03; pre-funded warrants for 9,078,529 shares at $22.029.
- Gross proceeds expected ~$400.0M; closing expected September 15, 2026.
- Net proceeds to advance dabogratinib in LG-UTUC, IR NMIBC, and achondroplasia programs.
- Offering led by RA Capital; Jefferies, Guggenheim, Cantor, Barclays, William Blair as book-runners.
- Warrants exercisable at $0.001; beneficial ownership limits selectable up to 19.99%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312526390951/0001193125-26-390951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312526390951/d102025d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-390951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer